Focalin XR

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

May 1, 2005 → Jul 1, 2005

About Focalin XR

Focalin XR is a phase 3 stage product being developed by Novartis for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00141050. Target conditions include ADHD.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (3) Active (9)
atomoxetineEli LillyApproved
Strattera (atomoxetine)Eli LillyApproved
Atomoxetine + placeboEli LillyApproved
atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00141063Phase 3Completed
NCT00141050Phase 3Completed

Competing Products

20 competing products in ADHD

See all competitors